First-line targeted therapy shows strong antitumour activity in advanced lung cancer — but the benefit depends on the right biomarker
First-line targeted therapy shows strong antitumour activity in advanced lung cancer — but the benefit depends on the right biomarker Few areas of cancer medicine have changed as dramatically in recent years as the treatment of advanced lung cancer....
Read more







